Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pomalidomide”

252 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 252 results

Early research (Phase 1)UnknownNCT03015922
What this trial is testing

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Leeds 4
Large-scale testing (Phase 3)Ended earlyNCT03440411
What this trial is testing

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 9
Testing effectiveness (Phase 2)Study completedNCT03910244
What this trial is testing

Pomalidomide for the Treatment of Bleeding in HHT

Who this might be right for
Telangiectasia, Hereditary Hemorrhagic
The Cleveland Clinic 145
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Study completedNCT02963493
What this trial is testing

Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncopeptides AB 157
Testing effectiveness (Phase 2)Ended earlyNCT04243109
What this trial is testing

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma
Maimónides Biomedical Research Institute of Córdoba 6
Testing effectiveness (Phase 2)Ended earlyNCT01946152
What this trial is testing

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma-Light Chain OnlyRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
M.D. Anderson Cancer Center 21
Large-scale testing (Phase 3)Looking for participantsNCT06561854
What this trial is testing

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Who this might be right for
Multiple MyelomaRelapse Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 318
Large-scale testing (Phase 3)Study completedNCT01178281
What this trial is testing

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Who this might be right for
Primary MyelofibrosisMPN-associated Myelofibrosis
Celgene 267
Early research (Phase 1)Ended earlyNCT01078974
What this trial is testing

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Who this might be right for
Waldenstrom's Macroglobulinemia
Steven P. Treon, MD, PhD 7
Large-scale testing (Phase 3)UnknownNCT03143049
What this trial is testing

Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Who this might be right for
Relapse Multiple Myeloma
National University Hospital, Singapore 120
Post-approval studies (Phase 4)UnknownNCT04989140
What this trial is testing

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04764942
What this trial is testing

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Mayo Clinic 39
Testing effectiveness (Phase 2)UnknownNCT03113942
What this trial is testing

Study of Pomalidomide in Anal Cancer Precursors

Who this might be right for
High Grade Squamous Intra-epithelial Lesion (HSIL)
Kirby Institute 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT02542657
What this trial is testing

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Who this might be right for
Myeloma
Joseph Tuscano 30
Testing effectiveness (Phase 2)Study completedNCT01432600
What this trial is testing

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Who this might be right for
Myeloma
H. Lee Moffitt Cancer Center and Research Institute 80
Testing effectiveness (Phase 2)Study completedNCT03731832
What this trial is testing

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
GWT-TUD GmbH 66
Large-scale testing (Phase 3)Study completedNCT01734928
What this trial is testing

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 559
Testing effectiveness (Phase 2)UnknownNCT02004275
What this trial is testing

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Alliance for Clinical Trials in Oncology 118
Post-approval studies (Phase 4)Study completedNCT05555329
What this trial is testing

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

Who this might be right for
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, Refractory
Amsterdam UMC, location VUmc 12
Load More Results